(Q96302550)

English

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation

scientific article published on 11 June 2020

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

F Heidel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

A Hochhaus

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

publication date

11 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of tofacitinib treatment on human B-cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-0898-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/S41375-020-0898-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32528040%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q96302550&oldid=1516986231"